Full Prescribing Info
Dosage/Direction for Use

Adult: 50-100 mg 2-3 times daily.
Renal impairment:
Contraindicated in marked renal impairment.
Hepatic impairment: Contraindicated in marked hepatic impairment.
Na or K depletion, adrenal gland failure, hyperchloraemic acidosis, and hepatic cirrhosis. Marked hepatic or renal impairment. Not to be used for long-term treatment of angle-closure glaucoma.
Special Precautions
Patient w/ pulmonary obstruction or emphysema, prediabetes or DM. Pregnancy and lactation. Monitoring Parameters Monitor CBC, platelet count and serum electrolytes periodically.
Adverse Reactions
Paraesthesia, hearing dysfunction or tinnitus, fatigue, malaise, loss of appetite, taste alteration, GI disturbances (e.g. nausea, vomiting, diarrhoea), polyuria, drowsiness, confusion, metabolic acidosis, electrolyte imbalance, transient myopia, urticaria, melaena, haematuria, glycosuria, hepatic insufficiency, flaccid paralysis, photosensitivity, convulsions. Rarely, crystalluria and renal calculi.
Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anaemia, and other blood dyscrasias.
Drug Interactions
Concomitant use w/ high-dose aspirin may result to anorexia, tachypnoea, lethargy, coma and death. Concomitant use w/ steroids may result to hypokalaemia.
Methazolamide inhibits carbonic anhydrase resulting to decreased secretion of aqueous humour, thus decreasing intraocular pressure.
Onset: 2-4 hr.
Duration: 10-18 hr.
Absorption: Well absorbed from the GI tract. Time to peak plasma concentration: 1-2 hr.
Distribution: Distributed throughout the body including the plasma, CSF, aqueous humour of eye, RBC, bile and extra-cellular fluid. Volume of distribution: 17-23 L. Plasma protein binding: Approx 55%.
Metabolism: Partially metabolised hepatically.
Excretion: Via urine (approx 15-30%). Elimination half-life: Approx 14 hr.
Oral: Store between 15-30°C.
ATC Classification
S01EC05 - methazolamide ; Belongs to the class of carbonic anhydrase inhibitors. Used in the treatment of glaucoma.
Disclaimer: This information is independently developed by CIMS based on methazolamide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in